We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

44 hedge funds and large institutions have $568M invested in Ambrx Biopharma Inc in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

277% more call options, than puts

Call options by funds: $17.6M | Put options by funds: $4.66M

143% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 7

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

5% more funds holding

Funds holding: 42 → 44 (+2)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

28% less capital invested

Capital invested by funds: $789M → $568M (-$220M)

Holders
44
Holders Change
+2
Holders Change %
+4.76%
% of All Funds
0.7%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
16
Increased
17
Reduced
7
Closed
13
Calls
$17.6M
Puts
$4.66M
Net Calls
+$12.9M
Net Calls Change
+$12M

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$32.6M
2
PBA
Paradigm Biocapital Advisors
New York
+$25M
3
CC
Commodore Capital
New York
+$4.68M
4
CAM
Cormorant Asset Management
Massachusetts
+$4.19M
5
GTC
Ghost Tree Capital
New York
+$3.91M

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$37.3M
2
AG
Artal Group
Luxembourg
-$11.6M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.12M
4
Holocene Advisors
Holocene Advisors
New York
-$5.82M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
DGM
1
Darwin Global Management
Jersey
$192M – – –
CAM
2
Cormorant Asset Management
Massachusetts
$114M +$4.19M +307,534 +3%
D.E. Shaw & Co
3
D.E. Shaw & Co
New York
$46.1M -$155K -11,395 -0.3%
CC
4
Commodore Capital
New York
$40.5M +$4.68M +343,556 +11%
PBA
5
Paradigm Biocapital Advisors
New York
$40.1M +$25M +1,838,097 +111%
Federated Hermes
6
Federated Hermes
Pennsylvania
$27.6M +$32.6M +2,395,867 New
VA
7
VR Adviser
New York
$23.8M -$5.65M -414,960 -17%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$20.3M -$6.12M -449,560 -20%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$9.45M -$1.47M -107,753 -12%
Citadel Advisors
10
Citadel Advisors
Florida
$8.84M +$569K +41,803 +6%
GTC
11
Ghost Tree Capital
New York
$6.04M +$3.91M +286,775 +120%
ECM
12
ExodusPoint Capital Management
New York
$5.67M +$216K +15,835 +3%
Holocene Advisors
13
Holocene Advisors
New York
$5.6M -$5.82M -427,192 -47%
Millennium Management
14
Millennium Management
New York
$5.34M +$2.44M +178,917 +63%
ABG
15
Ally Bridge Group
New York
$3.23M +$3.83M +281,089 New
Macquarie Group
16
Macquarie Group
Australia
$2.88M +$3.41M +250,000 New
HS
17
HighVista Strategies
Massachusetts
$2.23M +$548K +40,270 +26%
NM
18
NWI Management
New York
$1.85M +$2.19M +160,935 New
PHP
19
Parkman Healthcare Partners
Connecticut
$1.73M +$2.04M +150,000 New
First Manhattan
20
First Manhattan
New York
$1.55M – – –
LGM
21
Logos Global Management
California
$1.32M +$1.57M +115,000 New
TD Asset Management
22
TD Asset Management
Ontario, Canada
$1.27M +$636K +46,728 +73%
MIM
23
Monashee Investment Management
Massachusetts
$805K +$953K +70,000 New
Simplex Trading
24
Simplex Trading
Illinois
$788K +$843K +61,917 +933%
Manulife (Manufacturers Life Insurance)
25
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$682K +$1.16K +85 +0.1%
1
2 3

AMAM Hedge Fund Activity: Q3 2023 in Review

44 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q3 2023, worth a combined $568M — down 28% from $789M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AMAM positions and 13 closed out — a net gain of 3 holders — while 17 added to existing stakes and 7 trimmed.

The largest buyer was Federated Hermes, opening a new position worth an estimated $32.6M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $37.3M sold.

  • 44 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q3 2023, up from 42 in Q2 2023.
  • Funds reported $568M of Ambrx Biopharma Inc stock for Q3 2023, down 28% quarter-over-quarter.
  • 16 funds opened new Ambrx Biopharma Inc positions in Q3 2023 and 13 closed out, a net change of +3 holders.
  • The largest Ambrx Biopharma Inc buyer in Q3 2023 was Federated Hermes, an estimated $32.6M added.
  • The largest Ambrx Biopharma Inc seller in Q3 2023 was Farallon Capital Management, an estimated $37.3M sold.

Based on aggregated 13F filings for Q3 2023.